These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18077611

  • 1. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
    Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, Azrolan N, Sutradhar SC, Wang WW, Chan IS, Schlienger K, Schödel F, Silber JL, Zostavax Protocol 010 Study Group.
    Clin Vaccine Immunol; 2008 Feb; 15(2):314-9. PubMed ID: 18077611
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.
    Arnou R, Fiquet A, Thomas S, Sadorge C.
    Hum Vaccin; 2011 Oct; 7(10):1060-5. PubMed ID: 21941091
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL.
    Vaccine; 2010 Jun 07; 28(25):4204-9. PubMed ID: 20416263
    [Abstract] [Full Text] [Related]

  • 7. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA, Chen LK, Huang KC.
    Vaccine; 2015 Mar 24; 33(13):1515-7. PubMed ID: 25681662
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, Zhao Y, Parrino J, Popmihajlov Z.
    Clin Infect Dis; 2017 Oct 01; 65(7):1174-1182. PubMed ID: 29126292
    [Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
    Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, Meechan C, Li D, Schlienger K, Chan I, Sadoff J, Schödel F, Silber JL.
    Vaccine; 2007 Mar 01; 25(11):2139-44. PubMed ID: 17250932
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M, Heineman TC, Lal H.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1051-1058. PubMed ID: 28068212
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity, Safety, and Tolerability of Live Attenuated VaricellaZoster Virus Vaccine (ZOSTAVAX™) in Healthy Adults in India.
    Sreenivasamurthy L, Pandey S, Chandra BS, Sharma M, Ranganathaiah SR, Vaidya P, Naik R.
    J Assoc Physicians India; 2018 Jul 04; 66(7):50-54. PubMed ID: 31325263
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, Pagnoni MF, Stek JE, Xu J, Annunziato PW, Chan IS, Silber JL.
    Hum Vaccin; 2010 Nov 04; 6(11):894-902. PubMed ID: 20980796
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
    Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A.
    Hum Vaccin Immunother; 2013 Apr 04; 9(4):858-64. PubMed ID: 23319176
    [Abstract] [Full Text] [Related]

  • 18. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H.
    Vaccine; 2017 Dec 04; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
    Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW, Protocol 009 Study Group.
    Vaccine; 2007 Feb 26; 25(10):1877-83. PubMed ID: 17227688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.